Michael Davidson
Overview
Explore the profile of Michael Davidson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
252
Citations
9038
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krivoy A, Tiihonen J, Nissan J, Dotan A, Arnheim D, Menkes-Caspi N, et al.
Schizophr Bull
. 2025 Feb;
PMID: 39982759
Background: Guidelines issued by professional organizations recommend that all patients with psychotic disorders who have had several psychotic relapses, continue maintenance anti-psychotic treatment. However, some patients discontinue anti-psychotics and do...
2.
Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100744.
PMID: 39802819
Introduction: SCLC is characterized by aggressiveness and limited treatment options, especially in extensive-stage SCLC (ES-SCLC). Immunotherapy added to the platinum-etoposide combination has recently become standard in this setting. This retrospective...
3.
Saporta-Wiesel L, Feldman R, Levi L, Davidson M, Burshtein S, Gur R, et al.
Schizophr Bull Open
. 2024 Nov;
5(1):sgae022.
PMID: 39502135
Some but not other studies on oxytocin for schizophrenia, particularly those using a higher dose, indicate that oxytocin improves negative symptoms of schizophrenia. We performed an add-on randomized controlled trial...
4.
Chen Y, Davidson M, Liu Y, Liu D, Zhang H, Wang C, et al.
iScience
. 2024 Nov;
27(11):111041.
PMID: 39493881
China, holding nearly half of the global coal-fired power capacity, must shift from its coal-centric energy system to meet climate and air quality goals. This study explores the optimal utilization...
5.
Luykx J, Visscher R, Rossum I, Waters P, de Witte L, Fleischhacker W, et al.
Lancet Psychiatry
. 2024 Sep;
11(10):828-838.
PMID: 39300641
Background: Antibodies against the N-methyl-D-aspartate receptor (NMDAR) have been described in the serum of people with schizophrenia spectrum disorders (schizophrenia). However, the prevalence and clinical relevance of these antibodies in...
6.
Stefanescu C, Davidson M
Dialogues Clin Neurosci
. 2024 Aug;
26(1):53-55.
PMID: 39150448
Introduction: Antidiabetic drugs, reduction of carbohydrates intake, maintaining normal weight and physical activity are the cornerstone of diabetes 2 treatment. Methods: This opinion article is not intended to challenge hundreds...
7.
Daniel D, Cohen A, Velligan D, Harvey P, Alphs L, Davidson M, et al.
Schizophr Bull Open
. 2024 Aug;
4(1):sgad001.
PMID: 39145343
In contrast to the validated scales for face-to-face assessment of negative symptoms, no widely accepted tools currently exist for remote monitoring of negative symptoms. Remote assessment of negative symptoms can...
8.
Harvey P, Davidson M, Saoud J, Kuchibhatla R, Moore R, Depp C, et al.
Schizophr Res
. 2024 Jul;
271:246-252.
PMID: 39059248
Negative symptoms are a source of disability in schizophrenia, but criteria for identifying patients for clinical trials are in flux. Minimum severity for negative symptoms is paired with a definition...
9.
James S, Ahmed A, Harvey P, Saoud J, Davidson M, Kuchibhatla R, et al.
Eur Neuropsychopharmacol
. 2024 Jul;
87:18-23.
PMID: 39024856
Roluperidone, a 5-HT, sigma, and ɑ-adrenergic receptor antagonist, has proven efficacious for treating negative symptoms of schizophrenia in phase 2b and phase 3 clinical trials. Using network analysis, we demonstrated...
10.
Pergola P, Davidson M, Jensen C, Mohseni Zonoozi A, Raj D, Schytz P, et al.
J Am Soc Nephrol
. 2023 Dec;
35(1):74-84.
PMID: 38088558
Significance Statement: Systemic inflammation in CKD can lead to anemia. Ziltivekimab, a fully human monoclonal antibody targeting the IL-6 ligand, has been shown to reduce systemic inflammation in patients with...